<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD Journal Publishing DTD v2.3 20070202//EN" "journalpublishing.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" article-type="research-article" dtd-version="2.3" xml:lang="EN">
<front>
<journal-meta>
<journal-id journal-id-type="publisher-id">Front. Public Health</journal-id>
<journal-title>Frontiers in Public Health</journal-title>
<abbrev-journal-title abbrev-type="pubmed">Front. Public Health</abbrev-journal-title>
<issn pub-type="epub">2296-2565</issn>
<publisher>
<publisher-name>Frontiers Media S.A.</publisher-name>
</publisher>
</journal-meta>
<article-meta>
<article-id pub-id-type="doi">10.3389/fpubh.2025.1666408</article-id>
<article-categories>
<subj-group subj-group-type="heading">
<subject>Public Health</subject>
<subj-group>
<subject>Original Research</subject>
</subj-group>
</subj-group>
</article-categories>
<title-group>
<article-title>Global burden of HIV, syphilis, and HBV infection among women of childbearing age and children under five: based on the Global Burden of Diseases Study 2021</article-title>
</title-group>
<contrib-group>
<contrib contrib-type="author">
<name>
<surname>Lian</surname>
<given-names>Jia</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/writing-original-draft/"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Ke</surname>
<given-names>Bihong</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Zhang</surname>
<given-names>Xiaosheng</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Jinbo</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/formal-analysis/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Li</surname>
<given-names>Yandi</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author">
<name>
<surname>Wang</surname>
<given-names>Keke</given-names>
</name>
<xref ref-type="aff" rid="aff5"><sup>5</sup></xref>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Feng</surname>
<given-names>Yongliang</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1644440/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
<contrib contrib-type="author" corresp="yes">
<name>
<surname>Wang</surname>
<given-names>Suping</given-names>
</name>
<xref ref-type="aff" rid="aff1"><sup>1</sup></xref>
<xref ref-type="aff" rid="aff2"><sup>2</sup></xref>
<xref ref-type="aff" rid="aff3"><sup>3</sup></xref>
<xref ref-type="aff" rid="aff4"><sup>4</sup></xref>
<xref ref-type="corresp" rid="c001"><sup>&#x002A;</sup></xref>
<uri xlink:href="https://loop.frontiersin.org/people/1541713/overview"/>
<role content-type="https://credit.niso.org/contributor-roles/conceptualization/"/>
<role content-type="https://credit.niso.org/contributor-roles/data-curation/"/>
<role content-type="https://credit.niso.org/contributor-roles/funding-acquisition/"/>
<role content-type="https://credit.niso.org/contributor-roles/methodology/"/>
<role content-type="https://credit.niso.org/contributor-roles/software/"/>
<role content-type="https://credit.niso.org/contributor-roles/writing-review-editing/"/>
</contrib>
</contrib-group>
<aff id="aff1"><sup>1</sup><institution>Department of Epidemiology, School of Public Health, Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>, <country>China</country></aff>
<aff id="aff2"><sup>2</sup><institution>Center of Clinical Epidemiology and Evidence Based Medicine, Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>, <country>China</country></aff>
<aff id="aff3"><sup>3</sup><institution>MOE Key Laboratory of Coal Environmental Pathogenicity and Prevention, Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>, <country>China</country></aff>
<aff id="aff4"><sup>4</sup><institution>Research Center for Reverse Microbial Etiology, Workstation of Academician, Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>, <country>China</country></aff>
<aff id="aff5"><sup>5</sup><institution>First Hospital of Shanxi Medical University</institution>, <addr-line>Taiyuan</addr-line>, <country>China</country></aff>
<author-notes>
<fn fn-type="edited-by" id="fn0002">
<p>Edited by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/2037783/overview">Enos Moyo</ext-link>, University of KwaZulu-Natal, South Africa</p>
</fn>
<fn fn-type="edited-by" id="fn0003">
<p>Reviewed by: <ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/1230601/overview">Tafadzwa Dzinamarira</ext-link>, ICAP in Zimbabwe, Zimbabwe</p>
<p><ext-link ext-link-type="uri" xlink:href="https://loop.frontiersin.org/people/3068507/overview">Derek Mangoya</ext-link>, Leefrecht B.V, Namibia</p>
</fn>
<corresp id="c001">&#x002A;Correspondence: Suping Wang, <email>supingwang@sxmu.edu.cn</email>; Yongliang Feng, <email>yongliang.feng@sxmu.edu.cn</email></corresp>
</author-notes>
<pub-date pub-type="epub">
<day>16</day>
<month>10</month>
<year>2025</year>
</pub-date>
<pub-date pub-type="collection">
<year>2025</year>
</pub-date>
<volume>13</volume>
<elocation-id>1666408</elocation-id>
<history>
<date date-type="received">
<day>15</day>
<month>07</month>
<year>2025</year>
</date>
<date date-type="accepted">
<day>26</day>
<month>09</month>
<year>2025</year>
</date>
</history>
<permissions>
<copyright-statement>Copyright &#x00A9; 2025 Lian, Ke, Zhang, Li, Li, Wang, Feng and Wang.</copyright-statement>
<copyright-year>2025</copyright-year>
<copyright-holder>Lian, Ke, Zhang, Li, Li, Wang, Feng and Wang</copyright-holder>
<license xlink:href="http://creativecommons.org/licenses/by/4.0/">
<p>This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.</p>
</license>
</permissions>
<abstract>
<sec id="sec1">
<title>Introduction</title>
<p>Human immunodeficiency virus (HIV), syphilis, and hepatitis B virus (HBV) infection pose a major global public health challenge. However, high-quality integrated data on the burden of these diseases among women of childbearing age (WCBA) and children remain limited. This study aims to provide a comprehensive global assessment of HIV, syphilis, and HBV infection among WCBA and children under five and to explore their potential relationships.</p>
</sec>
<sec id="sec2">
<title>Methods</title>
<p>The Global Burden of Disease Study 2021 provided data on the global prevalence of WCBA and incidence of HIV, syphilis, and HBV infection in children under five years old from 1990 to 2021. Temporal trends were analyzed using annual average percentage change (AAPC) and joinpoint regression. A Bayesian age-period-cohort model was used to forecast the disease burden from 2022 to 2030.</p>
</sec>
<sec id="sec3">
<title>Results</title>
<p>In 2021, the age-standardized prevalence (ASPR) of HIV infection among WCBA was 830.87 per 100,000, while the age-standardized incidence (ASIR) of HIV among children under five was 15.39 per 100,000. From 1990 to 2021, the ASPR of HIV in WCBA demonstrated sustained growth, whereas the ASIR in children exhibited a rise-then-fall pattern. For syphilis, the 2021 ASPR among WCBA was 1057.32 per 100,000, and the ASIR in children was 58.36 per 100,000; both metrics followed a declining-then-rising trend, returning to 1990 levels by 2021. Both the ASPR of HBV infection among WCBA and the ASIR among children under five declined significantly from 1990 to 2021, with average annual percentage changes of &#x2212;1.25% and &#x2212;4.14%, respectively. Generally, ASPR and ASIR decreased as the sociodemographic index (SDI) increased. Regions with lower SDI experienced a disproportionately higher burden of HIV, syphilis, and HBV infections.</p>
</sec>
<sec id="sec4">
<title>Conclusion</title>
<p>In 2021, the global disease burden of HIV, syphilis, and HBV infection remained high among WCBA and children under five, with significant regional and demographic disparities. These findings indicate a persistent public health challenge, necessitating continued global efforts to mitigate the burden through addressing socioeconomic inequalities, strengthening health education, and expanding healthcare access.</p>
</sec>
</abstract>
<kwd-group>
<kwd>global disease burden</kwd>
<kwd>women of child-bearing age</kwd>
<kwd>children under five</kwd>
<kwd>HIV</kwd>
<kwd>syphilis</kwd>
<kwd>HBV infection</kwd>
</kwd-group>
<counts>
<fig-count count="5"/>
<table-count count="0"/>
<equation-count count="0"/>
<ref-count count="41"/>
<page-count count="11"/>
<word-count count="6874"/>
</counts>
<custom-meta-wrap>
<custom-meta>
<meta-name>section-at-acceptance</meta-name>
<meta-value>Infectious Diseases: Epidemiology and Prevention</meta-value>
</custom-meta>
</custom-meta-wrap>
</article-meta>
</front>
<body>
<sec sec-type="intro" id="sec5">
<label>1</label>
<title>Introduction</title>
<p>Adolescent girls and young women (AGYW) constitute a vital demographic with significant social and economic potential. As a sexually active population, they face a higher risk of sexually transmitted infections (STIs). Decisions made during adolescence exert immediate and long-term effects on future economic opportunities, health trajectories, and skill acquisition. Women of child-bearing age (WCBA), defined as those aged 15&#x2013;59&#x202F;years, represent a critical population for reproductive health. Their infection status directly influences mother-to-child transmission (MTCT) rates and perinatal outcomes (<xref ref-type="bibr" rid="ref1">1</xref>). AGYW are a key subgroup within this broader WCBA demographic. Human immunodeficiency virus (HIV), syphilis, and hepatitis B virus (HBV) infection are significant sexually transmitted diseases and also represent major causes of MTCT. This transmission can occur during pregnancy, delivery, or breastfeeding, leading to substantial maternal and child morbidity, mortality, and long-term disease burden.</p>
<p>Epidemiological evidence indicates alarming transmission risks in untreated cases. Without intervention, the MTCT rate for HIV ranges from 15 to 45% (<xref ref-type="bibr" rid="ref2">2</xref>). Maternal HIV infection increases child mortality both directly and indirectly through associated complications. Similarly, neonates exposed to HBV face infection rates of 70&#x2013;90% when born to HBsAg- and HBeAg-positive mothers and 5&#x2013;20% for HBsAg-positive and HBeAg-negative mothers (<xref ref-type="bibr" rid="ref3">3</xref>). An estimated 90% of perinatally infected newborns develop chronic HBV infection and subsequent liver diseases, such as cirrhosis and hepatocellular carcinoma, far exceeding the 5% chronicity rate in adults. Untreated maternal syphilis is equally devastating, causing adverse pregnancy outcomes in approximately 70% of cases, including fetal loss, stillbirth, congenital syphilis, or neonatal death (<xref ref-type="bibr" rid="ref4">4</xref>).</p>
<p>HIV, syphilis, and HBV infection share common transmission routes, leading to frequent co-infections and complex interactions (<xref ref-type="bibr" rid="ref5">5</xref>). They are also driven by common social and structural determinants, including socio-economic inequality, limited access to education and sexual health services, and gender-based violence. Biologically, active syphilis infection increases susceptibility to HIV infection (<xref ref-type="bibr" rid="ref6">6</xref>), and HBV/HIV coinfection accelerates disease progression, resulting in a higher risk of liver deterioration than HBV mono-infection. Notably, HIV, syphilis, and HBV co-infections exhibit synergistic interactions that exacerbate disease progression and amplify MTCT risks, further complicating clinical management (<xref ref-type="bibr" rid="ref7">7</xref>). These findings underscore the urgent need to integrate epidemiological surveillance with targeted MTCT prevention strategies, emphasizing the lifelong health implications of perinatal infections.</p>
<p>Triple elimination refers to the initiative to eliminate the MTCT of HIV, syphilis, and HBV infection prevalent in low- and middle-income countries. This initiative aligns with the World Health Organization&#x2019;s (WHO) Global Health Sector Strategies (GHSS) on HIV, viral hepatitis, and STDs for 2022&#x2013;2030 (<xref ref-type="bibr" rid="ref8">8</xref>), supporting broader goals such as the Global Alliance to End AIDS in Children (<xref ref-type="bibr" rid="ref9">9</xref>) and the GHSS target to eliminate viral hepatitis as a public health threat by 2030. Furthermore, the 69th World Health Assembly in 2016 set a 90% reduction in global syphilis incidence by 2030 (<xref ref-type="bibr" rid="ref10">10</xref>). Given the interconnectedness of these diseases, HBV vaccination and syphilis screening for WCBA are also effective HIV prevention strategies. It is essential to estimate the disease burden of these infections among WCBA and children under five at national, regional, and sociodemographic index (SDI) levels. Such data are crucial for informing targeted interventions and accelerating progress toward triple elimination.</p>
<p>In this study, we utilized the Global Burden of Disease, Injuries, and Risk Factors Study (GBD) 2021 database (<xref ref-type="bibr" rid="ref11">11</xref>) to analyze the disease burden of HIV, syphilis, and HBV infection among WCBA and children under five globally and across subnational regions. By analyzing these epidemiological metrics, we aim to elucidate the association between maternal infections and adverse pediatric outcomes, highlighting the preventable burden of MTCT-related morbidity and mortality, and inform evidence-based policy frameworks to reduce perinatal transmission and alleviate chronic health consequences in affected children. The primary significance of this work lies in providing actionable insights to refine MTCT prevention strategies, optimize resource allocation, and advance progress toward triple elimination goals.</p>
</sec>
<sec sec-type="methods" id="sec6">
<label>2</label>
<title>Methods</title>
<sec id="sec7">
<label>2.1</label>
<title>Data sources</title>
<p>The data for this study were obtained from the GBD study 2021, which analyzed the disease burden of an estimated 371 diseases and injuries across 204 countries and territories (<xref ref-type="bibr" rid="ref11">11</xref>). We extracted data on incidence, prevalence, disability-adjusted life-years (DALYs), age-standardized incidence (ASIR), age-standardized prevalence (ASPR), and age-standardized DALY rate of WCBA and children under five. Age-specific and country-specific estimates were generated using the Global Health Data Exchange Query Tool<xref ref-type="fn" rid="fn0001"><sup>1</sup></xref> (<xref ref-type="bibr" rid="ref12">12</xref>). The disease burden attributable to HBV infection included acute HBV infection, HBV-induced liver cirrhosis, and hepatocellular carcinoma (HCC) secondary to chronic HBV infection.</p>
<p>The SDI, developed by GBD researchers and calculated for GBD study 2021, was used to assess the combined level of health-related social and economic development across countries and territories. The SDI is a composite indicator (ranging from 0 to 1) that incorporates a country&#x2019;s lag-distributed income per capita, average years of schooling, and total fertility rate among females under 25&#x202F;years. Based on the country-level SDI estimates for 2021, the 204 countries were categorized into quintiles: low, low-middle, middle, high-middle, and high.</p>
</sec>
<sec id="sec8">
<label>2.2</label>
<title>Data analysis</title>
<p>As the included data were stratified by age groups and time period, the age-standardized rate (ASR) based on the world standard population in the GBD database was used for analysis. We used the direct standardization method to calculate ASRs for specific age groups using the &#x201C;ageadjust.direct&#x201D; function from the &#x201C;epitools&#x201D; package in R software (<xref ref-type="bibr" rid="ref13 ref14 ref15">13&#x2013;15</xref>). Heterogeneity was assessed using 95% uncertainty intervals (UIs). Joinpoint regression model was used to estimate the average annual percentage change (AAPC) and corresponding 95% confidence intervals (CI) for each segment (<xref ref-type="bibr" rid="ref16">16</xref>). These models included both linear (y&#x202F;=&#x202F;xb) and log-linear (ln y&#x202F;=&#x202F;xb) forms. The log-linear model was applied to analyze population-based trends in ASRs in our study. The number and location of joinpoints were determined using the grid search method, allowing for a maximum of five joinpoints. Model optimization was performed using the Monte Carlo permutation test, following the methodology described in previous studies (<xref ref-type="bibr" rid="ref17">17</xref>).</p>
<p>To predict the future ASRs for HIV, syphilis and HBV infection, we utilized the Bayesian age&#x2013;period&#x2013;cohort (BAPC) model to analyze the incidence, prevalence, and DALY rate of these three MTCT diseases from 2022 to 2030. A key advantage of the BAPC model is its implementation of the Integrated Nested Laplacian Approximation (INLA) method, which approximates the posterior distribution and helps avoid mixing and convergence problems associated with traditional Bayesian methods of Markov Chain Monte Carlo sampling (<xref ref-type="bibr" rid="ref18">18</xref>). Due to its comprehensive coverage and ability to capture temporal trends, the BAPC model has been widely validated and applied in epidemiological research, particularly in studies involving age-structured population data and complex cohort effects (<xref ref-type="bibr" rid="ref18">18</xref>).</p>
<p>Joinpoint regression analysis was performed using the Joinpoint Regression Program (version 5.0.2.0) (<xref ref-type="bibr" rid="ref19">19</xref>). All data analyses and visualizations were conducted using R software (version 4.3.3). A <italic>p</italic>-value of &#x003C;&#x202F;0.05 (two-sided) was considered statistically significant.</p>
</sec>
</sec>
<sec sec-type="results" id="sec9">
<label>3</label>
<title>Results</title>
<sec id="sec10">
<label>3.1</label>
<title>Global overview</title>
<p>Globally, the number of prevalent HIV infection cases among WCBA increased dramatically from 3.55 million in 1990 to 16.49 million in 2021, representing a 364.51% increase over this period (<xref ref-type="fig" rid="fig1">Figure 1A</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary file 1</xref>). The ASPR also increased significantly from 1990 to 2021, with an AAPC of 3.85% (95% CI: 3.48&#x2013;4.22). Trend analysis revealed that the ASPR of HIV infection among WCBA increased markedly from 2001, stabilized during 2001 to 2009, and then gradually rose again in subsequent years. Conversely, the ASIR of HIV infection in children under 5&#x202F;years declined by 3.32% between 1990 and 2021, reaching 15.39 per 100,000 in 2021. The ASIR in this age group increased until 2002, peaked in that year, and subsequently decreased steadily (<xref ref-type="fig" rid="fig1">Figure 1B</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary file 2</xref>).</p>
<fig position="float" id="fig1">
<label>Figure 1</label>
<caption>
<p>Joinpoint regression analysis of HIV, syphilis, and HBV infection prevalence among WCBA and incidence among children under 5&#x202F;years globally, 1990&#x2013;2021. <bold>(A,C,E)</bold> ASPR among WCBA. <bold>(B,D,F)</bold> ASPR among children under 5&#x202F;years.</p>
</caption>
<graphic xlink:href="fpubh-13-1666408-g001.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Six graphs display trends in age-standardized prevalence and incidence rates for HIV, syphilis, and HBV infection from 1990 to 2021. Each graph highlights joinpoints where significant changes occurred, with lines in different colors representing changes in annual percent change (APC). Panels A and B show trends for HIV; panels C and D show trends for syphilis; panels E and F show trends for HBV infection. A legend provides APC values for each segment.</alt-text>
</graphic>
</fig>
<p>In 2021, there were 20.48 million prevalent cases of syphilis among WCBA worldwide. This represents a 103.98% increase from 1990, which had 10.04 million cases. Over the past 30&#x202F;years, the ASPR of syphilis among WCBA initially increased, then decreased until approximately 2010, reached its lowest point that year, and subsequently increased annually, with an accelerated upward trend after 2019 (<xref ref-type="fig" rid="fig1">Figure 1C</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary file 1</xref>). Among children under five, the ASIR of syphilis was 58.36 per 100,000 in 2021. The ASIR declined until 2016, reached its lowest level that year, and then increased sharply thereafter (<xref ref-type="fig" rid="fig1">Figure 1D</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary file 2</xref>).</p>
<p>HBV infection remains a major global public health issue. The number of prevalent HBV infections among WCBA was estimated at 74.15 million in 1990 and 73.35 million in 2021. The ASPR from HBV infection showed a declining trend, with an AAPC of &#x2212;1.25% (95%CI: &#x2212;1.28 to &#x2212;1.22) from 1990 to 2021 (<xref ref-type="fig" rid="fig1">Figure 1E</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary file 1</xref>). Trend analysis revealed a sustained and significant decline in the ASPR for HBV infection among WCBA over the past three decades, both globally and across all SDI regions. Globally, an estimated 2.82 million new cases of HBV infection occurred among children under 5&#x202F;years in 2021, corresponding to an ASIR of 429.60 per 100,000. Before 2019, this age group exhibited a consistent downward trend in HBV infection incidence, followed by a moderate increase (<xref ref-type="fig" rid="fig1">Figure 1F</xref>; <xref ref-type="supplementary-material" rid="SM1">Supplementary file 2</xref>).</p>
</sec>
<sec id="sec11">
<label>3.2</label>
<title>Regional differences</title>
<p>In 2021, the ASPR of HIV infection among WCBA was highest in Southern sub-Saharan Africa, followed closely by Eastern sub-Saharan Africa (<xref ref-type="fig" rid="fig2">Figure 2A</xref>). Globally, the ASPR of HIV infection among WCBA showed a significant upward trend from 1990 to 2021, except in Central Sub-Saharan Africa, where no significant increase was observed. The most pronounced rises occurred in Oceania (AAPC&#x202F;=&#x202F;17.29%), Eastern Europe (AAPC&#x202F;=&#x202F;12.84%), and South Asia (AAPC&#x202F;=&#x202F;12.10%) (<xref ref-type="supplementary-material" rid="SM1">Supplementary file 1</xref>; <xref ref-type="fig" rid="fig2">Figure 2B</xref>). Similarly, Southern and Eastern Sub-Saharan Africa had the highest ASIR of HIV infection among children under five in 2021 (<xref ref-type="fig" rid="fig3">Figure 3A</xref>). The ASIR of HIV infection in this pediatric population also exhibited considerable regional heterogeneity. The most substantial increases were observed in Eastern Europe (AAPC&#x202F;=&#x202F;10.30%), South Asia (AAPC&#x202F;=&#x202F;10.22%), and Oceania (AAPC&#x202F;=&#x202F;9.73%), whereas Australasia experienced the greatest decline (AAPC&#x202F;=&#x202F;&#x2212;7.62%) (<xref ref-type="supplementary-material" rid="SM1">Supplementary file 2</xref>; <xref ref-type="fig" rid="fig3">Figure 3B</xref>).</p>
<fig position="float" id="fig2">
<label>Figure 2</label>
<caption>
<p>ASPR and AAPC of HIV, syphilis, and HBV infection among WCBA, by country. <bold>(A,C,E)</bold> ASPR in 2021. <bold>(B,D,F)</bold> AAPC from 1990 to 2021.</p>
</caption>
<graphic xlink:href="fpubh-13-1666408-g002.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Maps illustrating HIV, syphilis, and HBV infection age-standardized prevalence and annual percentage change across global regions. Panels A, C, and E show prevalence, with red indicating high prevalence and blue indicating low. Panels B, D, and F depict annual percentage change, with green showing increases and red showing decreases. Insets highlight specific areas: Caribbean, Persian Gulf, Balkan Peninsula, Southeast Asia, West Africa, Eastern Europe, and Northern Europe, providing regional detail. Each map has a legend for color coding.</alt-text>
</graphic>
</fig>
<fig position="float" id="fig3">
<label>Figure 3</label>
<caption>
<p>ASIR and AAPC of HIV, syphilis, and HBV infection among children under 5&#x202F;years old, by country. <bold>(A,C,E)</bold> ASIR in 2021. <bold>(B,D,F)</bold> AAPC from 1990 to 2021.</p>
</caption>
<graphic xlink:href="fpubh-13-1666408-g003.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Maps show global incidence rates and annual percent changes (APC) for HIV, syphilis, and HBV infections. Panels A, C, and E depict age-standardized incidence with color-coded gradients indicating rates. Panels B, D, and F illustrate APC with shades representing percentage changes. Smaller maps detail specific regions, including the Caribbean, Balkan Peninsula, Southeast Asia, and Northern Europe. HIV maps (A and B) show high incidence in Sub-Saharan Africa and varying APC globally. Syphilis maps (C and D) indicate high concentration in Africa with moderate APC. HBV maps (E and F) highlight significant incidences in Africa with diverse APC patterns.</alt-text>
</graphic>
</fig>
<p>In 2021, Central, Southern, and Eastern Sub-Saharan Africa had the highest ASPR of syphilis among WCBA and the highest ASIR among children under five across all 21 regions (<xref ref-type="fig" rid="fig2">Figures 2C</xref>, <xref ref-type="fig" rid="fig3">3C</xref>). Notably, Southern Sub-Saharan Africa demonstrated the most substantial decline in ASPR from 1990 to 2021 (AAPC&#x202F;=&#x202F;&#x2212;2.33%), while Tropical Latin America exhibited the greatest increase (AAPC&#x202F;=&#x202F;1.26%) (<xref ref-type="supplementary-material" rid="SM1">Supplementary file 1</xref>; <xref ref-type="fig" rid="fig2">Figure 2D</xref>). From 1990 to 2021, Southern Asia experienced the most significant increase in ASIR of syphilis among children under five (AAPC&#x202F;=&#x202F;1.05%), while Andean Latin America showed the most substantial decline (AAPC&#x202F;=&#x202F;&#x2212;2.04%) (<xref ref-type="supplementary-material" rid="SM1">Supplementary file 2</xref>; <xref ref-type="fig" rid="fig3">Figure 3D</xref>).</p>
<p>The global burden of HBV infection among WCBA also showed distinct geographical patterns in 2021. While East and South Asia had the highest number of cases, Central and Western Sub-Saharan Africa bore the most severe disease burden, demonstrating the highest ASPR (<xref ref-type="fig" rid="fig2">Figure 2E</xref>). A consistent downward trend in HBV ASPR was observed across all GBD regions from 1990 to 2021. The most significant declines occurred in Central Europe (AAPC&#x202F;=&#x202F;&#x2212;2.46%), East Asia (AAPC&#x202F;=&#x202F;&#x2212;2.13%), and Central Latin America (AAPC&#x202F;=&#x202F;&#x2212;2.13%) (<xref ref-type="supplementary-material" rid="SM1">Supplementary file 1</xref>; <xref ref-type="fig" rid="fig2">Figure 2F</xref>). Similar to the patterns for syphilis, Southern, Eastern, and Central Sub-Saharan Africa had the highest ASIR of HBV infection among children under five between 1990 and 2021 (<xref ref-type="fig" rid="fig3">Figure 3E</xref>). Furthermore, East Asia (AAPC&#x202F;=&#x202F;&#x2212;9.36%) showed the most remarkable decrease in ASIR in this pediatric group, followed by Eastern Europe (AAPC&#x202F;=&#x202F;&#x2212;6.97%) (<xref ref-type="supplementary-material" rid="SM1">Supplementary file 2</xref>; <xref ref-type="fig" rid="fig3">Figure 3F</xref>).</p>
</sec>
<sec id="sec12">
<label>3.3</label>
<title>Age differences</title>
<p>We further analyzed the ASPR of three MTCT diseases among WCBA across different age groups (<xref ref-type="supplementary-material" rid="SM1">Supplementary file 3</xref>). For HIV infection, both ASPR and AAPC increased with age in groups below 40&#x2013;44&#x202F;years, with a slight decline observed in the 45&#x2013;49-year age group. The 40&#x2013;44-year group exhibited the highest ASPR (1,215.72 per 100,000 population) and the largest increase (AAPC&#x202F;=&#x202F;6.19%) among all seven groups. In contrast, the global syphilis ASPR among WCBA peaked at younger ages, with the highest value observed in the 25&#x2013;29-year age group, followed by a gradual decline with increasing age. Most age groups maintained stable ASPR levels during 2019&#x2013;2021. Regarding HBV infection, the highest ASPR was also found in the 25&#x2013;29-year age group, after which its prevalence decreases progressively with age. All age groups showed a declining trend in HBV infection prevalence between 2019 and 2021, with the most pronounced decrease occurring in the 15&#x2013;19-year age group.</p>
</sec>
<sec id="sec13">
<label>3.4</label>
<title>Trends and proportions at different SDI levels</title>
<p>We further investigated the association between the SDI and the prevalence among WCBA and incidence among children under five for the three diseases globally. The results demonstrated significant inverse correlations between SDI and disease burden metrics, with all three diseases exhibiting decreasing trends in ASPR and ASIR as SDI increased.</p>
<p>Significant geographical heterogeneity was observed in the ASPR and DALYs among WCBA and ASIR and DALYs among children under 5 years old for the three MTCT diseases in 2021. Among WCBA, Southern sub-Saharan Africa had the highest HIV infection prevalence and DALYs rate, while Central sub-Saharan Africa showed the highest prevalence rates for both syphilis and HBV infection (<xref ref-type="fig" rid="fig4">Figures 4A</xref>,<xref ref-type="fig" rid="fig4">B</xref>). Among children under 5 years old, Oceania exhibited the highest HBV infection incidence, while Southern sub-Saharan Africa showed the highest incidence and DALYs rates for HIV infection (<xref ref-type="fig" rid="fig5">Figures 5A</xref>,<xref ref-type="fig" rid="fig5">B</xref>).</p>
<fig position="float" id="fig4">
<label>Figure 4</label>
<caption>
<p>Proportion of prevalent cases and DALYs attributable to each infection among WCBA across 21 GBD regions, 2021. ASPR, age-standardized prevalence rate; DALYs, disability-adjusted life years.</p>
</caption>
<graphic xlink:href="fpubh-13-1666408-g004.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Four bar charts depict data on HIV, syphilis, and HBV infection. Chart A shows age-standardized prevalence rates, with high rates in Sub-Saharan Africa. Chart B displays age-standardized DALYs rates, also highlighting high rates in Sub-Saharan Africa. Chart C illustrates the proportion of prevalence by disease, with HIV being prominent globally. Chart D presents the proportion of DALYs, again showing significant impact from HIV. The bars are color-coded: red for HIV, blue for syphilis, and green for HBV.</alt-text>
</graphic>
</fig>
<fig position="float" id="fig5">
<label>Figure 5</label>
<caption>
<p>Proportion of new cases and DALYs attributable to each infection among children under 5&#x202F;years old across 21 GBD regions, 2021. ASPR, age-standardized prevalence rate; DALYs, disability-adjusted life years.</p>
</caption>
<graphic xlink:href="fpubh-13-1666408-g005.tif" mimetype="image" mime-subtype="tiff">
<alt-text content-type="machine-generated">Four-panel bar charts compare age-standardized rates and proportions of incident cases and DALYs for HIV, syphilis, and HBV across regions and income groups. Panel A shows incidence rates, with HBV being the most prominent. Panel B displays DALYs rates, highlighting HIV. Panel C indicates incident case proportions, with HIV and syphilis varying significantly by region. Panel D presents DALY proportions, showing HIV as dominant in many regions. Each panel uses distinct colors for diseases: red for HIV, blue for syphilis, and green for HBV.</alt-text>
</graphic>
</fig>
<p>In 2021, HBV showed the highest prevalence among WCBA, whereas HIV infection imposed the greatest DALYs burden across most regions (<xref ref-type="fig" rid="fig4">Figures 4C</xref>,<xref ref-type="fig" rid="fig4">D</xref>). For children under five, HBV infection dominated the number of incident cases, while syphilis caused the most substantial DALYs burden (<xref ref-type="fig" rid="fig5">Figures 5C</xref>,<xref ref-type="fig" rid="fig5">D</xref>).</p>
</sec>
<sec id="sec14">
<label>3.5</label>
<title>Prediction of global prevalence and DALYs among WCBA</title>
<p>Using the BAPC model, we predicted the ASPR and age-standardized DALY rate in the next 10&#x202F;years. Our projections indicate a decline in the ASPR for both HIV and HBV infections from 2022 to 2030, whereas the prevalence of syphilis is expected to increase. The age-standardized DALY rate for HIV infection is projected to rise across all age groups. In contrast, the rates of syphilis and HBV infection are projected to remain relatively stable or show a slight decrease during the same period (<xref ref-type="supplementary-material" rid="SM1">Supplementary file 4</xref>).</p>
</sec>
</sec>
<sec sec-type="discussion" id="sec15">
<label>4</label>
<title>Discussion</title>
<p>Since the onset of the COVID-19 pandemic, a significant resurgence in STIs has been observed globally, particularly among young adults, including those in high-income countries. This study provides a comprehensive estimation of the global prevalence among WCBA and incidence in children under five for three major MTCT infections&#x2014;HIV, syphilis, and HBV infections&#x2014;from 1990 to 2021, with predictions of prevalence trends among WCBA over the next decade. This targeted analysis delineates the global epidemiological landscape of these infections and offers evidence-based insights to inform public health policies and optimize intervention strategies at national and global levels.</p>
<sec id="sec16">
<label>4.1</label>
<title>Global overview</title>
<p>After three decades, the worldwide HIV response remains a significant health challenge, compounded by the ever-expanding population of people living with HIV (<xref ref-type="bibr" rid="ref20">20</xref>). Consistent with previous studies, the ASPR of HIV among WCBA was increased globally from 1990 to 2021. HIV can be transmitted from infected mothers to their children during pregnancy, childbirth, or breastfeeding. More than 95% of pediatric HIV infections are attributable to MTCT. This transmission route carries substantial morbidity and mortality risks, particularly for neonates with immature immune systems, who are vulnerable to rapid disease progression and opportunistic infections (<xref ref-type="bibr" rid="ref21">21</xref>). Owing to the implementation of enhanced prevention and control strategies worldwide, the ASIR of HIV among children under five decreased globally after 2002.</p>
<p>The prevalence of syphilis has been reported to correlate closely with HIV prevalence (<xref ref-type="bibr" rid="ref22">22</xref>). This association may be due to factors that enhance the general transmission of STIs. Although syphilis can cause severe complications across all age groups, contemporary treatment strategies typically enable successful management of young adults. Overall, the disease burden of syphilis decreased before 2010, which may be attributed to improved access to antimicrobial treatment. Our findings are consistent with those of a previous study by Tao Chen et al. (<xref ref-type="bibr" rid="ref23">23</xref>). Antibiotics are the most effective treatment for syphilis. However, with the widespread use of antimicrobial agents, antimicrobial resistance has become a growing threat to syphilis control (<xref ref-type="bibr" rid="ref24">24</xref>). Furthermore, young people with multiple and occasional sexual partners, including men who have sex with men (MSMs), are at particularly high risk (<xref ref-type="bibr" rid="ref25">25</xref>), which increases the likelihood of infection among WCBA. Untreated maternal infection can lead to adverse pregnancy outcomes, including congenital syphilis, which remains a major contributor to global morbidity and mortality. In developing countries, maternal syphilis infection contributes to thousands of stillbirths and neonatal deaths each year (<xref ref-type="bibr" rid="ref26">26</xref>). Consistent with the disease burden observed among WCBA, the global burden of syphilis in children under five has also increased in recent years. Global health surveillance data also indicate a marked rise in the incidence of syphilis in children (<xref ref-type="bibr" rid="ref27">27</xref>). Strengthening maternal and neonatal health services, improving maternal education, expanding prenatal interventions, and enhancing monitoring systems for affected youth are critical strategies to reduce the burden of syphilis (<xref ref-type="bibr" rid="ref28">28</xref>).</p>
<p>HBV infection is the sixth leading cause of death worldwide and continues to pose a substantial global burden, affecting an estimated 296 million people. Of particular concern is that this population includes more than 6 million children under five (<xref ref-type="bibr" rid="ref29">29</xref>). Globally, the disease burden of HBV infection among WCBA and 0&#x2013;5-year-old children has shown a downward trend over the past three decades. This decline is largely attributable to the extensive implementation of global preventive measures, such as enhanced birth dose vaccination, prenatal hepatitis B screening, and risk reduction services, as well as increased research on functional cures for HBV infection (<xref ref-type="bibr" rid="ref30">30</xref>).</p>
</sec>
<sec id="sec17">
<label>4.2</label>
<title>Regional differences</title>
<p>Sub-Saharan Africa bears a disproportionate burden of the global HIV epidemic, accounting for approximately 67% of all people living with HIV worldwide (<xref ref-type="bibr" rid="ref31">31</xref>). In this study, the highest prevalence of HIV among WCBA and children under five was also observed in regions of sub-Saharan Africa (including Central, Eastern, Southern, and Western), indicating that the HIV burden in these regions remains the most severe. However, these regions also demonstrated the most pronounced decline in DALY rate, likely attributable to concerted governmental efforts to mitigate the epidemic. Notably, the 2013 Ministerial Commitment on Comprehensive Sexuality Education and Sexual and Reproductive Health and Rights in Eastern and Southern Africa represents one of the most robust policy initiatives aimed at reducing new HIV infections among young women by addressing early and unintended pregnancies (<xref ref-type="bibr" rid="ref32">32</xref>). It should be noted that the burden of HIV has increased significantly in Eastern Europe. According to UNAIDS, only 62% of people living with HIV in this region were aware of their status, and 51% received HIV treatment, resulting in an overall viral suppression rate of 48% (<xref ref-type="bibr" rid="ref33">33</xref>). The region has implemented a comprehensive strategy encompassing enhanced preventive measures, widespread legal advocacy, targeted community education for high-risk populations, and efforts to reduce social discrimination, collectively contributing to controlling the HIV disease burden (<xref ref-type="bibr" rid="ref34">34</xref>).</p>
<p>The geographical pattern of syphilis among women aged 15&#x2013;49&#x202F;years and children under five in our study was consistent with previous findings, showing that sub-Saharan Africa, Latin America, and Oceania had the highest burden (<xref ref-type="bibr" rid="ref35">35</xref>). The increased prevalence of syphilis among pregnant women in East and Southeast Asia and sub-Saharan Africa from 2000 to 2020 may be related to the growing proportion of the sexually active population aged 15&#x2013;64&#x202F;years, particularly in sub-Saharan Africa (<xref ref-type="bibr" rid="ref36">36</xref>). For children, the incidence of congenital syphilis rose significantly between 2015 and 2021. Potential contributing factors include a parallel increase in primary and secondary syphilis cases among WCBA, insufficient antenatal screening and appropriate treatment, and possible reinfection during pregnancy (<xref ref-type="bibr" rid="ref37">37</xref>).</p>
<p>The ASPR among WCBA and ASIR among children under five decreased with regional heterogeneity. Globally, an estimated 4.5 million women with chronic HBV infection give birth each year, with the highest burden concentrated in Africa and the Western Pacific regions (<xref ref-type="bibr" rid="ref30">30</xref>). Among GBD regions, East Asia had the largest decrease in prevalence among WCBA and incidence among children under five between 1990 and 2021. Universal infant immunization provided at no cost may be a key contributor to reducing the prevalence of chronic HBV infection in this region. China achieved a remarkable public health success by reducing the prevalence of chronic HBV infection by 90%, attributable to comprehensive healthcare system reforms supported by strong political and financial commitments (<xref ref-type="bibr" rid="ref38">38</xref>). Western and Central sub-Saharan Africa had the largest disease burden from HBV infection worldwide in 2021. This may be due to poor postnatal coverage of hepatitis B vaccines, including low rates of timely birth administration for infants, ineffective screening programs in the general population, and lower disease awareness compared to other regions (<xref ref-type="bibr" rid="ref39">39</xref>).</p>
</sec>
<sec id="sec18">
<label>4.3</label>
<title>SDI differences</title>
<p>Our findings indicate a significant inverse correlation between the SDI and the overall disease burden of HIV, syphilis, and HBV infection. These inverse correlations suggest that socioeconomic development plays a crucial role in reducing the burden of MTCT diseases. The disparities in HIV burden are multifactorial, with low-SDI regions exhibiting a higher prevalence of complex socioeconomic and structural challenges&#x2014;including poverty, systemic inequities, HIV-related stigma, and barriers to healthcare access&#x2014;compared to high-SDI regions (<xref ref-type="bibr" rid="ref40">40</xref>). In some low SDI and middle-low SDI regions, the observed increase in syphilis prevalence may reflect improved diagnostic capabilities, leading to increased case detection and reporting (<xref ref-type="bibr" rid="ref41">41</xref>). Our study found that the substantial disease burden of HIV, syphilis, and HBV infections remains high in low SDI and middle-low SDI regions. Therefore, comprehensive strategies for effective control and management, including screening, health education, and syndromic management, should be implemented in these regions.</p>
</sec>
<sec id="sec19">
<label>4.4</label>
<title>Future perspectives</title>
<p>Achieving the World Health Organization (WHO) targets for eliminating MTCT of HIV, syphilis, and hepatitis B remains a major public health challenge across all regions. Our study projects a decline in the ASPR of both HIV and HBV infections between 2022 and 2030, whereas the prevalence of syphilis is anticipated to increase during the same period. Reducing infection prevalence among WCBA is a powerful dual-benefit strategy that not only safeguards women&#x2019;s own health but also serves as primary prevention for children, thereby breaking the cycle of intergenerational transmission. These infections share several characteristics that support an integrated public health approach: they can be readily diagnosed, and their MTCT can be effectively prevented through similar interventions.</p>
<p>The WHO advocates a coordinated &#x201C;triple elimination&#x201D; initiative to simultaneously eliminate MTCT of HIV, syphilis, and hepatitis B. The cornerstone of this strategy is to screen all pregnant women for HIV, syphilis, and hepatitis B surface antigen as early as possible during pregnancy (<xref ref-type="bibr" rid="ref30">30</xref>). In recent years, a growing number of countries have implemented national campaigns aligned with this initiative. Significant progress has been observed in several regions, with 15 countries and territories having received WHO validation for eliminating MTCT of syphilis and/or HIV. Nevertheless, sustaining and expanding these achievements requires strengthened political commitment, robust policy frameworks, and comprehensive prevention, screening, and treatment programs. These efforts are particularly critical in lower SDI regions, where health systems face greater challenges in reducing new infections and mortality among women and children and achieving complete MTCT elimination (<xref ref-type="bibr" rid="ref8">8</xref>).</p>
</sec>
<sec id="sec20">
<label>4.5</label>
<title>Limitations</title>
<p>This study has several limitations. First, the primary data were obtained from the GBD study 2021. The GBD study 2021 estimates rely more heavily on data from economically developed countries, and the accuracy of raw data in some low- and middle-income countries may be limited, which is an inherent constraint of the dataset. Second, diagnostic criteria and detection methods vary across regions and over time. Surveillance and data collection systems may be less robust or incomplete for some or all of these infections among WCBA and infants. It should be noted that while many middle- and lower-income countries now have relatively robust HIV surveillance systems, HBV testing and surveillance are generally weaker, and syphilis detection and reporting capabilities are often substantially less developed.</p>
</sec>
</sec>
<sec sec-type="conclusions" id="sec21">
<label>5</label>
<title>Conclusion</title>
<p>This study utilized data from the GBD study 2021 to estimate the disease burdens of HIV, syphilis, and HBV infection among WCBA and children under five. The findings reveal distinct epidemiological trajectories for each infection. The ASPR of HIV among WCBA continues to increase, whereas the ASIR of HIV among children under five initially rose before declining. This pattern suggests that pediatric interventions have had a mitigating effect, though greater efforts targeting women are still urgently needed. Globally, both the ASPR of syphilis in WCBA and the ASIR among children under five decreased initially between 1990 and 2021, but have since rebounded, indicating a resurgence that warrants enhanced screening, treatment, and public health attention. In contrast, widespread vaccination and prevention efforts have contributed to a consistent decline in HBV infection burden among both populations. Nevertheless, current progress remains insufficient to meet the WHO 2030 viral hepatitis elimination targets, particularly in low- and middle-income SDI regions, where intensified efforts are critical.</p>
</sec>
</body>
<back>
<sec sec-type="data-availability" id="sec22">
<title>Data availability statement</title>
<p>The original contributions presented in the study are included in the article/<xref ref-type="supplementary-material" rid="SM1">Supplementary material</xref>, further inquiries can be directed to the corresponding author.</p>
</sec>
<sec sec-type="author-contributions" id="sec23">
<title>Author contributions</title>
<p>JiaL: Writing &#x2013; original draft, Conceptualization, Data curation, Formal analysis, Methodology, Software. BK: Formal analysis, Methodology, Software, Writing &#x2013; review &#x0026; editing. XZ: Formal analysis, Methodology, Software, Writing &#x2013; review &#x0026; editing. JinL: Formal analysis, Methodology, Software, Writing &#x2013; review &#x0026; editing. YL: Software, Writing &#x2013; review &#x0026; editing. KW: Software, Writing &#x2013; review &#x0026; editing. YF: Funding acquisition, Software, Writing &#x2013; review &#x0026; editing. SW: Conceptualization, Data curation, Funding acquisition, Methodology, Software, Writing &#x2013; review &#x0026; editing.</p>
</sec>
<sec sec-type="funding-information" id="sec24">
<title>Funding</title>
<p>The author(s) declare that financial support was received for the research and/or publication of this article. This study was supported by the National Natural Science Foundation of China (grant numbers 82073622 and 81872677).</p>
</sec>
<ack>
<p>The authors express their gratitude to the Institute for Health Metrics and Evaluation for sharing valuable GBD data.</p>
</ack>
<sec sec-type="COI-statement" id="sec25">
<title>Conflict of interest</title>
<p>The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.</p>
</sec>
<sec sec-type="ai-statement" id="sec26">
<title>Generative AI statement</title>
<p>The authors declare that no Gen AI was used in the creation of this manuscript.</p>
<p>Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.</p>
</sec>
<sec sec-type="disclaimer" id="sec27">
<title>Publisher&#x2019;s note</title>
<p>All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.</p>
</sec>
<sec sec-type="supplementary-material" id="sec28">
<title>Supplementary material</title>
<p>The Supplementary material for this article can be found online at: <ext-link xlink:href="https://www.frontiersin.org/articles/10.3389/fpubh.2025.1666408/full#supplementary-material" ext-link-type="uri">https://www.frontiersin.org/articles/10.3389/fpubh.2025.1666408/full#supplementary-material</ext-link></p>
<supplementary-material xlink:href="Supplementary_file_1.docx" id="SM1" mimetype="application/vnd.openxmlformats-officedocument.wordprocessingml.document" xmlns:xlink="http://www.w3.org/1999/xlink"/>
</sec>
<fn-group>
<fn id="fn0001"><p><sup>1</sup><ext-link xlink:href="http://ghdx.healthdata.org/gbd-results-tool" ext-link-type="uri">http://ghdx.healthdata.org/gbd-results-tool</ext-link></p></fn>
</fn-group>
<ref-list>
<title>References</title>
<ref id="ref1"><label>1.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sun</surname><given-names>P</given-names></name> <name><surname>Yu</surname><given-names>C</given-names></name> <name><surname>Yin</surname><given-names>L</given-names></name> <name><surname>Chen</surname><given-names>Y</given-names></name> <name><surname>Sun</surname><given-names>Z</given-names></name> <name><surname>Zhang</surname><given-names>T</given-names></name> <etal/></person-group>. <article-title>Global, regional, and national burden of female cancers in women of child-bearing age, 1990-2021: analysis of data from the global burden of disease study 2021</article-title>. <source>EClinicalMedicine</source>. (<year>2024</year>) <volume>74</volume>:<fpage>102713</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2024.102713</pub-id>, PMID: <pub-id pub-id-type="pmid">39050105</pub-id></citation></ref>
<ref id="ref2"><label>2.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kurewa</surname><given-names>EN</given-names></name> <name><surname>Gumbo</surname><given-names>FZ</given-names></name> <name><surname>Munjoma</surname><given-names>MW</given-names></name> <name><surname>Mapingure</surname><given-names>MP</given-names></name> <name><surname>Chirenje</surname><given-names>MZ</given-names></name> <name><surname>Rusakaniko</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>Effect of maternal HIV status on infant mortality: evidence from a 9-month follow-up of mothers and their infants in Zimbabwe</article-title>. <source>J Perinatol: official journal of the California Perinatal Association</source>. (<year>2010</year>) <volume>30</volume>:<fpage>88</fpage>&#x2013;<lpage>92</lpage>. doi: <pub-id pub-id-type="doi">10.1038/jp.2009.121</pub-id>, PMID: <pub-id pub-id-type="pmid">19693024</pub-id></citation></ref>
<ref id="ref3"><label>3.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Nelson</surname><given-names>NP</given-names></name> <name><surname>Jamieson</surname><given-names>DJ</given-names></name> <name><surname>Murphy</surname><given-names>TV</given-names></name></person-group>. <article-title>Prevention of perinatal hepatitis B virus transmission</article-title>. <source>J Pediatr Infect Dis Soc</source>. (<year>2014</year>) <volume>3</volume>:<fpage>S7</fpage>&#x2013;<lpage>s12</lpage>. doi: <pub-id pub-id-type="doi">10.1093/jpids/piu064</pub-id>, PMID: <pub-id pub-id-type="pmid">25232477</pub-id></citation></ref>
<ref id="ref4"><label>4.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Hawkes</surname><given-names>S</given-names></name> <name><surname>Matin</surname><given-names>N</given-names></name> <name><surname>Broutet</surname><given-names>N</given-names></name> <name><surname>Low</surname><given-names>N</given-names></name></person-group>. <article-title>Effectiveness of interventions to improve screening for syphilis in pregnancy: a systematic review and meta-analysis</article-title>. <source>Lancet Infect Dis</source>. (<year>2011</year>) <volume>11</volume>:<fpage>684</fpage>&#x2013;<lpage>91</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1473-3099(11)70104-9</pub-id>, PMID: <pub-id pub-id-type="pmid">21683653</pub-id></citation></ref>
<ref id="ref5"><label>5.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name> <name><surname>Ren</surname><given-names>Q</given-names></name> <name><surname>Chang</surname><given-names>W</given-names></name></person-group>. <article-title>Epidemiological features and risk factors for acquiring hepatitis B, hepatitis C, and syphilis in HIV-infected patients in Shaanxi Province, Northwest China</article-title>. <source>Int J Environ Res Public Health</source>. (<year>2020</year>) <volume>17</volume>:<fpage>17</fpage>. doi: <pub-id pub-id-type="doi">10.3390/ijerph17061990</pub-id>, PMID: <pub-id pub-id-type="pmid">32197326</pub-id></citation></ref>
<ref id="ref6"><label>6.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Buchacz</surname><given-names>K</given-names></name> <name><surname>Patel</surname><given-names>P</given-names></name> <name><surname>Taylor</surname><given-names>M</given-names></name> <name><surname>Kerndt</surname><given-names>PR</given-names></name> <name><surname>Byers</surname><given-names>RH</given-names></name> <name><surname>Holmberg</surname><given-names>SD</given-names></name> <etal/></person-group>. <article-title>Syphilis increases HIV viral load and decreases CD4 cell counts in HIV-infected patients with new syphilis infections</article-title>. <source>AIDS</source>. (<year>2004</year>) <volume>18</volume>:<fpage>2075</fpage>&#x2013;<lpage>9</lpage>. doi: <pub-id pub-id-type="doi">10.1097/00002030-200410210-00012</pub-id>, PMID: <pub-id pub-id-type="pmid">15577629</pub-id></citation></ref>
<ref id="ref7"><label>7.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll1">World Health Organization</collab></person-group>. <article-title>Prevention of mother-to-child transmission of HIV, hepatitis B and C and syphilis</article-title> (<year>2021</year>). Available online at: <ext-link xlink:href="https://www.who.int/publications/m/item/prevention-of-mother-to-child-transmission-of-HIV-hepatitis-b-and-c-and-syphilis" ext-link-type="uri">https://www.who.int/publications/m/item/prevention-of-mother-to-child-transmission-of-HIV-hepatitis-b-and-c-and-syphilis</ext-link> [Accessed Apr 2, 2025].</citation></ref>
<ref id="ref8"><label>8.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll2">World Health Organization</collab></person-group>. <article-title>Global health sector strategies on, respectively, HIV, viral hepatitis and sexually transmitted infections for the period 2022-2030</article-title> (<year>2022</year>). Available online at: <ext-link xlink:href="https://iris.who.int/handle/10665/360348" ext-link-type="uri">https://iris.who.int/handle/10665/360348</ext-link> [Accessed Apr 2, 2025].</citation></ref>
<ref id="ref9"><label>9.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll3">UNAIDS</collab></person-group>. <article-title>The global Alliance to end AIDS in children</article-title> (<year>2022</year>). Available online at: <ext-link xlink:href="https://www.unaids.org/en/resources/documents/2022/global-alliance-end-AIDS-in-children" ext-link-type="uri">https://www.unaids.org/en/resources/documents/2022/global-alliance-end-AIDS-in-children</ext-link> [Accessed Apr 2, 2025].</citation></ref>
<ref id="ref10"><label>10.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll4">World Health Organization</collab></person-group>. <article-title>Global health sector strategy on sexually transmitted infections, 2016-2021</article-title> (<year>2016</year>). Available online at: <ext-link xlink:href="https://www.who.int/publications/i/item/WHO-RHR-16.09" ext-link-type="uri">https://www.who.int/publications/i/item/WHO-RHR-16.09</ext-link> [Accessed Apr 2, 2025].</citation></ref>
<ref id="ref11"><label>11.</label> <citation citation-type="journal"><person-group person-group-type="author"><collab id="coll1001">GBD 2021 Diseases and Injuries Collaborators</collab></person-group>. <article-title>Global incidence, prevalence, years lived with disability (YLDs), disability-adjusted life-years (DALYs), and healthy life expectancy (HALE) for 371 diseases and injuries in 204 countries and territories and 811 subnational locations, 1990-2021: a systematic analysis for the global burden of disease study 2021</article-title>. <source>Lancet</source>. (<year>2024</year>) <volume>403</volume>:<fpage>2133</fpage>&#x2013;<lpage>61</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0140-6736(24)00757-8</pub-id></citation></ref>
<ref id="ref12"><label>12.</label> <citation citation-type="journal"><person-group person-group-type="author"><collab id="coll1002">GBD 2019 Diseases and Injuries Collaborators</collab></person-group>. <article-title>Global burden of 369 diseases and injuries in 204 countries and territories, 1990-2019: a systematic analysis for the global burden of disease study 2019</article-title>. <source>Lancet</source>. (<year>2020</year>) <volume>396</volume>:<fpage>1204</fpage>&#x2013;<lpage>22</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s0140-6736(20)30925-9</pub-id></citation></ref>
<ref id="ref13"><label>13.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Fay</surname><given-names>MP</given-names></name> <name><surname>Feuer</surname><given-names>EJ</given-names></name></person-group>. <article-title>Confidence intervals for directly standardized rates: a method based on the gamma distribution</article-title>. <source>Stat Med</source>. (<year>1997</year>) <volume>16</volume>:<fpage>791</fpage>&#x2013;<lpage>801</lpage>. doi: <pub-id pub-id-type="doi">10.1002/(sici)1097-0258(19970415)16:7&#x003C;791::aid-sim500&#x003E;3.0.co;2-#</pub-id>, PMID: <pub-id pub-id-type="pmid">9131766</pub-id></citation></ref>
<ref id="ref14"><label>14.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Anderson</surname><given-names>RN</given-names></name> <name><surname>Rosenberg</surname><given-names>HM</given-names></name></person-group>. <article-title>Age standardization of death rates: implementation of the year 2000 standard</article-title>. <source>Natl Vital Stat Rep</source>. (<year>1998</year>) <volume>47</volume>:<fpage>20</fpage>.</citation></ref>
<ref id="ref15"><label>15.</label> <citation citation-type="book"><person-group person-group-type="author"><name><surname>Selvin</surname><given-names>S</given-names></name></person-group>. <source>Statistical analysis of epidemiologic data</source>. <publisher-loc>New York</publisher-loc>: <publisher-name>Oxford University Press</publisher-name> (<year>2004</year>).</citation></ref>
<ref id="ref16"><label>16.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Li</surname><given-names>J</given-names></name> <name><surname>Bai</surname><given-names>H</given-names></name> <name><surname>Gao</surname><given-names>Z</given-names></name> <name><surname>Gao</surname><given-names>L</given-names></name> <name><surname>Wang</surname><given-names>W</given-names></name> <name><surname>Li</surname><given-names>Y</given-names></name> <etal/></person-group>. <article-title>Global, regional, and national temporal trends in incidence and mortality for liver cancer due to hepatitis B, 1990-2021: a decomposition and age-period-cohort analysis for the global burden of disease study 2021</article-title>. <source>Hepatol Int</source>. (<year>2024</year>) <volume>19</volume>:<fpage>368</fpage>&#x2013;<lpage>83</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12072-024-10765-4</pub-id>, PMID: <pub-id pub-id-type="pmid">39702656</pub-id></citation></ref>
<ref id="ref17"><label>17.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zhang</surname><given-names>C</given-names></name> <name><surname>Liu</surname><given-names>Y</given-names></name> <name><surname>Zhao</surname><given-names>H</given-names></name> <name><surname>Wang</surname><given-names>G</given-names></name></person-group>. <article-title>Global, regional, and national burdens of cirrhosis in children and adolescents aged under 19 years from 1990 to 2019</article-title>. <source>Hepatol Int</source>. (<year>2024</year>) <volume>18</volume>:<fpage>238</fpage>&#x2013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1007/s12072-023-10531-y</pub-id>, PMID: <pub-id pub-id-type="pmid">37101103</pub-id></citation></ref>
<ref id="ref18"><label>18.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Bai</surname><given-names>Z</given-names></name> <name><surname>Han</surname><given-names>J</given-names></name> <name><surname>An</surname><given-names>J</given-names></name> <name><surname>Wang</surname><given-names>H</given-names></name> <name><surname>Du</surname><given-names>X</given-names></name> <name><surname>Yang</surname><given-names>Z</given-names></name> <etal/></person-group>. <article-title>The global, regional, and national patterns of change in the burden of congenital birth defects, 1990-2021: an analysis of the global burden of disease study 2021 and forecast to 2040</article-title>. <source>EClinicalMedicine</source>. (<year>2024</year>) <volume>77</volume>:<fpage>102873</fpage>. doi: <pub-id pub-id-type="doi">10.1016/j.eclinm.2024.102873</pub-id>, PMID: <pub-id pub-id-type="pmid">39416384</pub-id></citation></ref>
<ref id="ref19"><label>19.</label> <citation citation-type="other"><article-title>Application for windows command-line (batch/callable) version of Joinpoint regression software</article-title>. Available online at: <ext-link xlink:href="https://surveillance.cancer.gov/joinpoint/callable/" ext-link-type="uri">https://surveillance.cancer.gov/joinpoint/callable/</ext-link> [Accessed Apr 3, 2024]</citation></ref>
<ref id="ref20"><label>20.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chicanequisso</surname><given-names>EM</given-names></name> <name><surname>Sabonete</surname><given-names>A</given-names></name> <name><surname>Sacarlal</surname><given-names>J</given-names></name> <name><surname>Rossetto</surname><given-names>&#x00C9;V</given-names></name> <name><surname>Cassimo</surname><given-names>MN</given-names></name> <name><surname>Baltazar</surname><given-names>CS</given-names></name></person-group>. <article-title>Factors associated with HIV infection among adolescents and young people in Mozambique: sub-analysis of immunization, malaria and HIV/AIDS indicator survey in Mozambique-IMASIDA 2015</article-title>. <source>BMC Public Health</source>. (<year>2025</year>) <volume>25</volume>:<fpage>2932</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s12889-025-24122-z</pub-id>, PMID: <pub-id pub-id-type="pmid">40866892</pub-id></citation></ref>
<ref id="ref21"><label>21.</label> <citation citation-type="book"><person-group person-group-type="author"><name><surname>Abbas</surname><given-names>M</given-names></name> <name><surname>Bakhtyar</surname><given-names>A</given-names></name> <name><surname>Bazzi</surname><given-names>R</given-names></name></person-group>. <source>Neonatal HIV</source>. <publisher-loc>Treasure Island</publisher-loc>: <publisher-name>StatPearls Publishing LLC</publisher-name> (<year>2025</year>).</citation></ref>
<ref id="ref22"><label>22.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Kenyon</surname><given-names>CR</given-names></name> <name><surname>Osbak</surname><given-names>K</given-names></name> <name><surname>Tsoumanis</surname><given-names>A</given-names></name></person-group>. <article-title>The global epidemiology of syphilis in the past century - a systematic review based on antenatal syphilis prevalence</article-title>. <source>PLoS Negl Trop Dis</source>. (<year>2016</year>) <volume>10</volume>:<fpage>e0004711</fpage>. doi: <pub-id pub-id-type="doi">10.1371/journal.pntd.0004711</pub-id>, PMID: <pub-id pub-id-type="pmid">27167068</pub-id></citation></ref>
<ref id="ref23"><label>23.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>T</given-names></name> <name><surname>Wan</surname><given-names>B</given-names></name> <name><surname>Wang</surname><given-names>M</given-names></name> <name><surname>Lin</surname><given-names>S</given-names></name> <name><surname>Wu</surname><given-names>Y</given-names></name> <name><surname>Huang</surname><given-names>J</given-names></name></person-group>. <article-title>Evaluating the global, regional, and national impact of syphilis: results from the global burden of disease study 2019</article-title>. <source>Sci Rep</source>. (<year>2023</year>) <volume>13</volume>:<fpage>11386</fpage>. doi: <pub-id pub-id-type="doi">10.1038/s41598-023-38294-4</pub-id>, PMID: <pub-id pub-id-type="pmid">37452074</pub-id></citation></ref>
<ref id="ref24"><label>24.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Morehead</surname><given-names>MS</given-names></name> <name><surname>Scarbrough</surname><given-names>C</given-names></name></person-group>. <article-title>Emergence of global antibiotic resistance</article-title>. <source>Prim Care</source>. (<year>2018</year>) <volume>45</volume>:<fpage>467</fpage>&#x2013;<lpage>84</lpage>. doi: <pub-id pub-id-type="doi">10.1016/j.pop.2018.05.006</pub-id>, PMID: <pub-id pub-id-type="pmid">30115335</pub-id></citation></ref>
<ref id="ref25"><label>25.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Costa-Louren&#x00E7;o</surname><given-names>APR</given-names></name> <name><surname>Su</surname><given-names>X</given-names></name> <name><surname>Le</surname><given-names>W</given-names></name> <name><surname>Yang</surname><given-names>Z</given-names></name> <name><surname>Patts</surname><given-names>GJ</given-names></name> <name><surname>Massari</surname><given-names>P</given-names></name> <etal/></person-group>. <article-title>Epidemiological and clinical observations of gonococcal infections in women and prevention strategies</article-title>. <source>Vaccine</source>. (<year>2021</year>) <volume>9</volume>:<fpage>327</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines9040327</pub-id>, PMID: <pub-id pub-id-type="pmid">33915835</pub-id></citation></ref>
<ref id="ref26"><label>26.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Peeling</surname><given-names>RW</given-names></name> <name><surname>Mabey</surname><given-names>D</given-names></name> <name><surname>Kamb</surname><given-names>ML</given-names></name> <name><surname>Chen</surname><given-names>XS</given-names></name> <name><surname>Radolf</surname><given-names>JD</given-names></name> <name><surname>Benzaken</surname><given-names>AS</given-names></name></person-group>. <article-title>Syphilis</article-title>. <source>Nat Rev Dis Primers</source>. (<year>2017</year>) <volume>3</volume>:<fpage>17073</fpage>. doi: <pub-id pub-id-type="doi">10.1038/nrdp.2017.73</pub-id>, PMID: <pub-id pub-id-type="pmid">29022569</pub-id></citation></ref>
<ref id="ref27"><label>27.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Stafford</surname><given-names>IA</given-names></name> <name><surname>Workowski</surname><given-names>KA</given-names></name> <name><surname>Bachmann</surname><given-names>LH</given-names></name></person-group>. <article-title>Syphilis complicating pregnancy and congenital syphilis</article-title>. <source>N Engl J Med</source>. (<year>2024</year>) <volume>390</volume>:<fpage>242</fpage>&#x2013;<lpage>53</lpage>. doi: <pub-id pub-id-type="doi">10.1056/NEJMra2202762</pub-id>, PMID: <pub-id pub-id-type="pmid">38231625</pub-id></citation></ref>
<ref id="ref28"><label>28.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Duan</surname><given-names>B</given-names></name> <name><surname>Zhou</surname><given-names>Y</given-names></name> <name><surname>Wang</surname><given-names>X</given-names></name> <name><surname>Wang</surname><given-names>H</given-names></name> <name><surname>Li</surname><given-names>Y</given-names></name> <name><surname>Zhou</surname><given-names>X</given-names></name> <etal/></person-group>. <article-title>Congenital syphilis: adverse pregnancy outcomes and neonatal disorders</article-title>. <source>Infection</source>. (<year>2025</year>). doi: <pub-id pub-id-type="doi">10.1007/s15010-025-02591-z</pub-id>, PMID: <pub-id pub-id-type="pmid">40549329</pub-id></citation></ref>
<ref id="ref29"><label>29.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll5">CDC</collab></person-group>. <article-title>Fast facts: global hepatitis B vaccination</article-title> (<year>2024</year>). Available online at: <ext-link xlink:href="https://www.cdc.gov/global-hepatitis-b-vaccination/data-research/index.html" ext-link-type="uri">https://www.cdc.gov/global-hepatitis-b-vaccination/data-research/index.html</ext-link> [Accessed Mar 20, 2025].</citation></ref>
<ref id="ref30"><label>30.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll6">World Health Organization</collab></person-group>. <source>Global hepatitis report 2024: Action for access in low- and middle-income countries</source> (<year>2024</year>). Available online at: <ext-link xlink:href="https://iris.who.int/handle/10665/376461" ext-link-type="uri">https://iris.who.int/handle/10665/376461</ext-link> [Accessed Apr 2, 2025].</citation></ref>
<ref id="ref31"><label>31.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll7">UNAIDS.Global HIV &#x0026; AIDS statistics &#x2014; Fact sheet</collab></person-group> (<year>2025</year>). Available online at: <ext-link xlink:href="https://www.unaids.org/en/resources/fact-sheet" ext-link-type="uri">https://www.unaids.org/en/resources/fact-sheet</ext-link> [Accessed Aug 20, 2025].</citation></ref>
<ref id="ref32"><label>32.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Watson</surname><given-names>K</given-names></name> <name><surname>Akwara</surname><given-names>E</given-names></name> <name><surname>Machawira</surname><given-names>P</given-names></name> <name><surname>Bakaroudis</surname><given-names>M</given-names></name> <name><surname>Tallarico</surname><given-names>R</given-names></name> <name><surname>Chandra-Mouli</surname><given-names>V</given-names></name></person-group>. <article-title>The east and southern Africa ministerial commitment: a review of progress toward fulfilling young people's sexual and reproductive health and rights (2013-2018)</article-title>. <source>Sexual and reproductive health matters</source>. (<year>2021</year>) <volume>29</volume>:<fpage>1982186</fpage>. doi: <pub-id pub-id-type="doi">10.1080/26410397.2021.1982186</pub-id>, PMID: <pub-id pub-id-type="pmid">34726585</pub-id></citation></ref>
<ref id="ref33"><label>33.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Parczewski</surname><given-names>M</given-names></name> <name><surname>G&#x00F6;kengin</surname><given-names>D</given-names></name></person-group>. <article-title>The HIV epidemic in eastern Europe and Central Asia in difficult times: a story of resilience and change</article-title>. <source>J Int AIDS Soc</source>. (<year>2024</year>) <volume>27</volume>:<fpage>e26325</fpage>. doi: <pub-id pub-id-type="doi">10.1002/jia2.26325</pub-id>, PMID: <pub-id pub-id-type="pmid">39021069</pub-id></citation></ref>
<ref id="ref34"><label>34.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Gokengin</surname><given-names>D</given-names></name> <name><surname>Bursa</surname><given-names>D</given-names></name> <name><surname>Skrzat-Klapaczynska</surname><given-names>A</given-names></name> <name><surname>Alexiev</surname><given-names>I</given-names></name> <name><surname>Arsikj</surname><given-names>E</given-names></name> <name><surname>Balayan</surname><given-names>T</given-names></name> <etal/></person-group>. <article-title>PrEP scale-up and PEP in central and Eastern Europe: changes in time and the challenges we face with no expected HIV vaccine in the near future</article-title>. <source>Vaccine</source>. (<year>2023</year>) <volume>11</volume>:<fpage>122</fpage>. doi: <pub-id pub-id-type="doi">10.3390/vaccines11010122</pub-id>, PMID: <pub-id pub-id-type="pmid">36679967</pub-id></citation></ref>
<ref id="ref35"><label>35.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname><given-names>W</given-names></name> <name><surname>Chen</surname><given-names>Y</given-names></name> <name><surname>Cheng</surname><given-names>Z</given-names></name> <name><surname>Chen</surname><given-names>Y</given-names></name> <name><surname>Lv</surname><given-names>C</given-names></name> <name><surname>Ma</surname><given-names>L</given-names></name> <etal/></person-group>. <article-title>Global patterns of syphilis, gonococcal infection, typhoid fever, paratyphoid fever, diphtheria, pertussis, tetanus, and leprosy from 1990 to 2021: findings from the global burden of disease study 2021</article-title>. <source>Infect Dis Poverty</source>. (<year>2024</year>) <volume>13</volume>:<fpage>66</fpage>. doi: <pub-id pub-id-type="doi">10.1186/s40249-024-01231-2</pub-id>, PMID: <pub-id pub-id-type="pmid">39267116</pub-id></citation></ref>
<ref id="ref36"><label>36.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Zheng</surname><given-names>Y</given-names></name> <name><surname>Yu</surname><given-names>Q</given-names></name> <name><surname>Lin</surname><given-names>Y</given-names></name> <name><surname>Zhou</surname><given-names>Y</given-names></name> <name><surname>Lan</surname><given-names>L</given-names></name> <name><surname>Yang</surname><given-names>S</given-names></name> <etal/></person-group>. <article-title>Global burden and trends of sexually transmitted infections from 1990 to 2019: an observational trend study</article-title>. <source>Lancet Infect Dis</source>. (<year>2022</year>) <volume>22</volume>:<fpage>541</fpage>&#x2013;<lpage>51</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s1473-3099(21)00448-5</pub-id>, PMID: <pub-id pub-id-type="pmid">34942091</pub-id></citation></ref>
<ref id="ref37"><label>37.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>David</surname><given-names>A</given-names></name> <name><surname>Posfay-Barbe</surname><given-names>KM</given-names></name> <name><surname>Aguiar Nogueira</surname><given-names>C</given-names></name> <name><surname>Toutous Trellu</surname><given-names>L</given-names></name></person-group>. <article-title>Congenital syphilis in Switzerland: a marker of inequality? A mini-review</article-title>. <source>Front Public Health</source>. (<year>2023</year>) <volume>11</volume>:<fpage>1265725</fpage>. doi: <pub-id pub-id-type="doi">10.3389/fpubh.2023.1265725</pub-id>, PMID: <pub-id pub-id-type="pmid">37780442</pub-id></citation></ref>
<ref id="ref38"><label>38.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Meng</surname><given-names>Q</given-names></name></person-group>. <article-title>Strengthening public health systems in China</article-title>. <source>Lancet Public Health</source>. (<year>2022</year>) <volume>7</volume>:<fpage>e987</fpage>&#x2013;<lpage>8</lpage>. doi: <pub-id pub-id-type="doi">10.1016/s2468-2667(22)00206-7</pub-id>, PMID: <pub-id pub-id-type="pmid">36462519</pub-id></citation></ref>
<ref id="ref39"><label>39.</label> <citation citation-type="other"><person-group person-group-type="author"><collab id="coll8">World Health Organization</collab></person-group>. <article-title>Global progress report on HIV, viral hepatitis and sexually transmitted infections, 2021: accountability for the global health sector strategies 2016&#x2013;2021: actions for impact</article-title> (<year>2021</year>). Available online at: <ext-link xlink:href="https://iris.who.int/handle/10665/341412" ext-link-type="uri">https://iris.who.int/handle/10665/341412</ext-link> [Accessed Apr 2, 2025].</citation></ref>
<ref id="ref40"><label>40.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Powell</surname><given-names>AM</given-names></name></person-group>. <article-title>HIV infections and prevention in women</article-title>. <source>Clin Obstet Gynecol</source>. (<year>2025</year>) <volume>68</volume>:<fpage>159</fpage>&#x2013;<lpage>63</lpage>. doi: <pub-id pub-id-type="doi">10.1097/grf.0000000000000939</pub-id>, PMID: <pub-id pub-id-type="pmid">40128637</pub-id></citation></ref>
<ref id="ref41"><label>41.</label> <citation citation-type="journal"><person-group person-group-type="author"><name><surname>Sharma</surname><given-names>M</given-names></name> <name><surname>Rewari</surname><given-names>BB</given-names></name> <name><surname>Aditama</surname><given-names>TY</given-names></name> <name><surname>Turlapati</surname><given-names>P</given-names></name> <name><surname>Dallabetta</surname><given-names>G</given-names></name> <name><surname>Steen</surname><given-names>R</given-names></name></person-group>. <article-title>Control of sexually transmitted infections and global elimination targets, South-East Asia region</article-title>. <source>Bull World Health Organ</source>. (<year>2021</year>) <volume>99</volume>:<fpage>304</fpage>&#x2013;<lpage>11</lpage>. doi: <pub-id pub-id-type="doi">10.2471/blt.20.254003</pub-id>, PMID: <pub-id pub-id-type="pmid">33953448</pub-id></citation></ref>
</ref-list>
</back>
</article>